相关实验视频

Updated: May 7, 2026

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement

Published on: March 26, 2018

在患有显著隔膜缩的患者中,通过导管植入大动脉

Martin Beyer¹, Till Joscha Demal², Oliver D Bhadra²

¹Department of Cardiovascular Surgery, University Heart & Vascular Center Hamburg, Martinistraße 52, 20246, Hamburg, Germany. ma.beyer@uke.de.

Clinical research in cardiology : official journal of the German Cardiac Society

|March 11, 2024

概括

通过导管的大动脉植入 (TAVI) 的患者增加了室间隔膜深度 (IVSD) 显示了相似的急性结果,尽管压力梯度更高. 需要进一步的研究来评估长期门的耐用性.

科学领域:

心脏病学心脏病学
干预心脏病学干预心脏病学
心脏外科手术心脏外科手术

背景情况:

隔膜缩,定义为隔膜间隔膜深度 (IVSD) ≥14毫米,可能会复杂化跨导管大动脉植入 (TAVI).
潜在的并发症包括低于最佳的门部署,迁移和左心室外流通道 (LVOT) 升高的压力梯度.
之前的报道表明,这可能会对患者的治疗结果产生不利影响.

研究的目的:

为了研究间隔膜缩对TAVI后急性结局的影响.
为了比较TAVI接受的IVSD正常和增加的患者之间的程序和短期结果.

主要方法:

在2009年至2021年间,对1033名连续接受TAVI的患者进行了回顾性分析.
患者被分为两组:正常的IVSD (<14毫米) 和增加的IVSD (≥14毫米).
结果使用更新的门学术研究联盟-3 (VARC-3) 定义进行评估,并根据基线差异进行调整.

主要成果:

在增加IVSD组 (8.9 ± 4.9 mmHg与7.8 ± 4.1 mmHg) 中观察到显著更高的术后平均跨膜压力梯度.
在设备成功,技术成功,中度或重度的膜外泄,永久心脏起器植入率或30天死亡率方面没有发现显著差异.
两组之间,外接入率也是可比的.

结论:

增加的IVSD并没有对TAVI后的急性结果产生不利影响,尽管跨膜压力梯度较高.
这些发现表明,IVSD升高对TAVI成功没有直接的负面血液动力学影响.
对门耐用性的长期影响需要进一步研究.

关键词:

大动脉门狭窄症 Septal 缩症 Septal 缩症塔维 (Tavi) 是一个古老的城市.在TAVRR中,我们可以看到.

更多相关视频

Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement

Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement

Published on: January 20, 2022

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

相关概念视频

Mitral Stenosis III: Medical Management

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...

Aortic Regurgitation III: Medical Management

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...